Skip to main content
SpringerLink
Log in

Kymriah approved despite $475 000 price and toxicities

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Bach PB, et al. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. Journal of the American Medical Association : 20 Sep 2017. Available from: URL: http://dx.doi.org/10.1001/jama.2017.15218

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kymriah approved despite $475 000 price and toxicities. PharmacoEcon Outcomes News 789, 5 (2017). https://doi.org/10.1007/s40274-017-4412-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4412-y

Search

Navigation